Press Releases

Press Releases
Date Title and Summary View
Jan 29, 2018 Executive Chairman Bob Hugin to retire and step down from Celgene's Board of Directors effective February 5, 2018 During Bob Hugin's 19-year tenure, Celgene expanded from 200 to 7,500 employees, received approvals for 8 therapies across 10 diseases in more than 70 countries and delivered industry-...
Jan 25, 2018 - Finished 2017 with strong operating and financial momentum - Celgene recently announced two strategic transactions enhancing long-term growth prospects SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) reported operating results for the fourth quart...
Jan 22, 2018 Acquisition Will Add Novel Scientific Platform and Manufacturing Expertise to Celgene's Research and Operational Capabilities JCAR017 is Expected to be a Significant Growth Driver Beyond 2020 with Potential Global Peak Sales of Approximately $3B Reaffirming 2020 Fin...
Jan 19, 2018 Phase II LAPACT trial results reported on the safety and efficacy of ABRAXANE + gemcitabine induction therapy on tumor burden, disease control, and symptoms SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG) today announced primary endpoint findings and updated resul...
Jan 8, 2018 - Preliminary Q4 2017 total revenue of $3.5 billion, a 17 percent increase Y/Y - Preliminary FY 2017 total revenue of $13.0 billion, a 16 percent increase Y/Y - Reaffirming 2020 total revenue and adjusted diluted EPS financial targets SUMMIT,...
Jan 7, 2018 Fedratinib is a highly selective JAK2 kinase inhibitor that is being evaluated for myelofibrosis and polycythemia vera Fedratinib demonstrated clinical improvement in a phase III trial with treatment-naïve myelofibrosis patients and in a phase II trial with myelofibrosis patients ...
Jan 3, 2018 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG) will host a conference call and live audio webcast on Thursday, January 25, 2018 at 9 a.m. ET to discuss fourth quarter and full-year 2017 financial and operational results. The webcast can be accessed from the Investor Relations page at www.celge...
Jan 2, 2018 SUMMIT, N.J.--(BUSINESS WIRE)-- During the 36th Annual J.P. Morgan Healthcare Conference on January 8, 2018 at 10:30 a.m. ET, Celgene Corporation (NASDAQ: CELG) will present a business update on the Company in addition to preliminary unaudited 2017 financial results. The presentation and breakout session ...
Dec 21, 2017 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) and the Lymphoma Study Association (LYSA) today announced that the Lymphoma Academic Research Organisation (LYSARC) reported results from a phase III, randomized, open-label, international clinical study (RELEVANCE). This i...
Dec 11, 2017 —74% (14/19) ORR and 68% (13/19) CR rate at 3 months and 50% (7/14) CR at 6 months in core group at dose level 2— —Across doses, 80% (16/20) of core group patients in CR at month 3 remain in response at month 6; 92% (11/12) of core group patients in response at 6 months remain in...
FirstPrevious
2
... NextLast
Add to Briefcase = add release to Briefcase